Granulocyte-macrophage colony-stimulating factor variant
Patent Information
- Application Number
- JP2023525008
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-21
- Filing Date
- 2021-10-25
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current GM-CSF production systems produce a heterogeneous mixture of glycoforms, including hyperglycosylated species that are difficult to purify and can affect biological activity and bioavailability, leading to inconsistent pharmacokinetic properties.
Development of GM-CSF variants with specific amino acid substitutions or deletions at positions N37, E38, and T39 to reduce hyperglycosylation, allowing for simpler purification methods and improved glycoform profiles, including non-glycosylated, O-glycosylated, and N-glycosylated forms, without the need for organic solvents or reverse phase C4 HPLC columns.
The GM-CSF variants exhibit enhanced bioavailability, stability, and functional activity, with reduced hyperglycosylation, facilitating easier purification and potentially increasing production titers, while maintaining comparable biological activity to wild-type GM-CSF.
Smart Images

Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the interests and priority thereto of U.S. Provisional Patent Application No. 63 / 105,425 filed on 26 October 2020 and U.S. Provisional Patent Application No. 63 / 177,481 filed on 21 April 2021, the contents of which are incorporated herein by reference in their entirety.
[0002] The present invention generally relates to compositions and methods relating to mutant granulocyte-macrophage colony-stimulating factor (GM-CSF).
[0003] Sequence List This application includes a sequence listing submitted in ASCII format via EFS-Web, which is incorporated herein by reference in its entirety. This ASCII copy, created on October 20, 2021, is named "PNR-003PC_ST25.txt" and has a size of 4,096 bytes. [Background technology]
[0004] Colony-stimulating factors (CSFs) refer to a family of four glycoproteins that control and regulate cell production by widely dispersed and concentrated myeloid cells. These include granulocyte-macrophage CSF (GM-CSF), granulocyte colony CSF (G-CSF), macrophage colony CSF (M-CSF), and pluripotent colony-stimulating factor (IL-3). These lymphokines can induce progenitor cells found in the bone marrow to differentiate into specific types of mature blood cells. The specific type of mature blood cell that arises from the progenitor cells depends on the type of CSF present. See Metcalf D. Cancer Immunol Res. 2013, 1(6):351-356.
[0005] GM-CSF is a hematological growth factor that regulates the production, migration, proliferation, differentiation, and function of hematopoietic cells. In response to inflammatory stimuli, GM-CSF is released by various cell types, including T lymphocytes, macrophages, fibroblasts, and endothelial cells. Subsequently, GM-CSF activates and enhances the production and survival of neutrophils, eosinophils, and macrophages. Native GM-CSF is usually produced near the site of action that regulates the in vitro proliferation, differentiation, and survival of hematopoietic progenitor cells, but it is present in circulating blood at picomolar concentrations (10%). -10 from 10 -12 It exists only in M). See Alexander WS. Int Rev Immunol. 1998, 16: 651-682; Gasson JC. Blood. 1991, 77: 1131-1145; Shannon MF et al. Crit Rev Immunol. 1997, 17: 301-323, Barreda DR et al. Dev Comp Immunol. 2004, 28: 509-554, and Metcalf D. Immunol Cell Biology. 1987, 65: 35-43.
[0006] Human GM-CSF (hGM-CSF) is synthesized as a precursor protein of 144 amino acid residues containing a 17-amino acid signal peptide. Processing this precursor protein yields a mature protein of 127 amino acids with an estimated molecular weight of 14.4 kDa. This protein has two disulfide bonds and moves as a broad band of 15-30 kDa through glycosylation and sialylation. The N-linked glycan is Asn 27 and Asn 37Located at Ser5, Ser7, Ser9, and Ser10, there are several possible sites for O-linked glycosylation, but the degree of glycan structure at these sites has not been clearly determined. The glycosylation pattern of GM-CSF has been shown to affect its activity, receptor binding, immunogenicity, and half-life. See Lee F. et al. Proc Natl Acad Sci USA Biochem. 1985. 82:360-4364; Miyatake S. et al. EMBO J. 1985. 4:2561-2568; Cebon J et al. J Biol. Chem. 1991. 265, 4483-4491; Zhang Q et al. Proc. Natl. Acad. Sci. 2014, 2885-2890.
[0007] Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) is approved by the FDA for use in combination with chemotherapy in the treatment of neutropenia, hematological disorders, and malignancies such as leukemia. Clinically, GM-CSF used to treat chemotherapy-induced neutropenia and aplastic anemia significantly reduces the risk of infection associated with bone marrow transplantation. Its usefulness in the treatment of myeloid leukemia and as a vaccine adjuvant is also well established. See Dorr RT. Clin Therapeutics. 1993. 15(1):19-29; Armitage JO. Blood 1998, 92:4491-4508; Kovacic JC et al. J Mol Cell Cardiol. 2007, 42:19-33; Jacobs PP et al. Microbial Cell Factories 2010, 9:93.
[0008] There are five classes of heterologous protein production platforms, including bacterial, yeast, plant, insect, and mammalian cells. However, more than 50% of currently marketed biopharmaceuticals are produced in mammalian cell lines. This is partly due to the fact that the remaining four classes cannot modify glycoproteins with human-like oligosaccharides. This is important because protein-binding glycans affect circulating half-life, tissue distribution, biological activity, and immunogenicity.
[0009] GM-CSF expression systems affect the pharmacokinetic properties, biological activity, and clinical toxicity of GM-CSF. Clinically, GM-CSF is produced in Chinese hamster ovary cells (CHO-GM, reglamostim), Escherichia coli (E. coli-GM, morglamostim), or yeast (yeast-GM, salglamostim). See Dorr RT. Clin Therapeutics. 1993. 15(1):19-29; Walsh G. Nat Biotechnol. 2006, 24:769-776; Jacobs PP et al. Nat Protoc. 2009, 4:58-70; Jacobs PP et al. Microbial Cell Factories 2010, 9:93; Walsh G. Nat Biotechnol. 2018, 36(12):1136-1145. During the production of GM-CSF, four major GM-CSF isoforms / species exist: "highly glycosylated" species (approximately 50 kDa), N- and N-+O-glycosylated species (approximately 20 kDa), O-glycosylated species (approximately 16 kDa), and non-glycosylated species (approximately 15 kDa). Glycosylated GM-CSF is obtained only by recombinant technology using yeast (salglamostim) or Chinese hamster ovary (CHO) cells (reglamostim), producing a complex mixture of glycoforms, but not using E. coli. The heterogeneity of the glycans reflects a lack of specificity in posttranslational glycosylation in CHO cells. See Zhang Q et al. PNAS. 111(8):2885-2890.
[0010] The expression vector of sargramostim contains a leader sequence that directs transcription in the rough endoplasmic reticulum and secretion of mature GM-CSF by cells. N-glycosylation occurs when a glycan is added to the nitrogen of the asparagine (Asn) or arginine (Arg) side chain, while O-glycosylation occurs when a glycan is added to the hydroxyl oxygen side chain of serine (Ser), threonine (Thr), or tyrosine (Tyr) amino acids. Asparagine residues usually require a consensus sequence of Asn-Xxx-Ser / Thr / Cys (Xxx can be any amino acid other than proline) for N-glycosylation. The rhu GM-CSF protein sequence of sargramostim contains two consensus sequences, Asn-Leu-Ser (NLS) and Asn-Glu-Thr (NET), where the protein may be glycosylated. During the production of sargramostim, in some GM-CSF species present in the fermenter, both N-glycosylation sites of Asn 27 and Asn 37 are glycosylated. Thr 39 (or Ser 39 or Cys 39 ) residues are important anchors that enable glycosylation at Asn 27 or Asn 37 . Species with an N-oligosaccharide bound to asparagine residue 37 are called "highly glycosylated" species (30 - 100 kDa) because these glycoforms contain up to several hundred mannose residues. High-mannosylation occurs only at N37. In previous reports, mutagenesis that may affect glycosylation has been investigated (e.g., Gene 55:287 - 293 (1987) and Hehring Inst. Mitt. 83:1 - 7 (1988)), but these studies focused on protein yield and did not attempt to evaluate activity or rationalize the purification process (see Table 2 of Hehring Inst. Mitt. 83:1 - 7 (1988)).
[0011] In the upstream manufacturing process, four major GM-CSF species are present in the partially purified fermentation broth: a highly glycosylated species (approximately 50 kDa), N- and N-+O-glycosylated species (approximately 20 kDa, peak 2), an O-glycosylated species (approximately 16 kDa, peak 3), and a non-glycosylated species (approximately 15 kDa, peak 4). The highly glycosylated GM-CSF species is considered a non-product and is removed in the downstream process, yielding a product containing three major glycoforms (peaks 2-4), the bulk drug substance (BDS). In the T-0075 reversed-phase glycoform assay, small amounts of oxidized GM-CSF (≤4%) are detected in the BDS and DP, which is indicated as "peak 1". See Walter P, et al. JCB. 1981. 91(2 Pt1):545-50; Cantrell MA, et al. PNAS. 1985. 82:6250-6254. Most proteins synthesized in the rough endoplasmic reticulum undergo glycosylation, which is an enzyme-mediated, site-specific process. See Medzihradszky KF. Methods Mol Biol. 2008. 446:293-316. Varki A et al. Essentials of Glycobiology. Chapter 56. 3rd edition.
[0012] In addition to the three main rhu GM-CSF glycoforms currently present in the formulation, there is a "hyperglycosylated" form that accounts for less than 6% of the product. However, this "hyperglycosylated" form is not present in the current salglamostim (LEUKINE) formulation. The isolated "hyperglycosylated" species was estimated to contain two N-acetylglucosamine residues and an average of 43 mannose residues, which is at the lower end of the range known to be present in the fermentation broth. The species with an N-oligosaccharide bonded to asparagine residue 37 is called the "hyperglycosylated" species (30-100 kDa) because these glycoforms contain up to several hundred mannose residues. See Strenler KE, et al. 1994. This "hyperglycosylated" species is completely removed in the downstream purification process and is not detected at all in the final salglamostim bulk drug substance (BDS) used in the production of salglamostim.
[0013] The final product of salglamostim consists of N-glycosylated and O-glycosylated glycoforms and non-glycosylated glycoforms. Thus, salglamostim exhibits heterogeneity in its glycoform profile, and this heterogeneity has been remarkably consistent throughout its approval history. The three main glycoforms of salglamostim can be separated on an SDS-PAGE gel. The historical mean relative amounts of these three glycoforms have been fairly consistent at 28.68% ± 0.86%, 22.58% ± 0.73%, and 48.74% ± 0.8%, respectively. Nearly half of the GM-CSF protein in salglamostim is non-glycosylated, and slightly less than one-third is fully N-glycosylated. Most, if not all, of the N-glycosylated species are also O-glycosylated. The highly branched N-linked oligosaccharide structure covers a significant portion of the molecule, including the H1 and H5 alpha helices, without interfering with the receptor binding site or parts of the H6 alpha helix and C-terminal random coil.
[0014] While the carbohydrate components of recombinant GM-CSF differ based on the cell source, glycosylation is not required for receptor binding or in vitro and in vivo biological activity. Yeast rhu GM-CSF and non-glycosylated E. coli rhu GM-CSF have comparable specific activities, as measured by both receptor affinity and cell proliferation specific activity. See Urdal and Park, 1988; Metcalf D. Cancer 1990:65:2185-2195.
[0015] Human endogenous proteins are degraded in vivo at varying rates, depending on their function. For example, hemoglobin persists throughout the life of a red blood cell, and histones have half-lives of several years, while other proteins, such as ornithine decarboxylase (half-life 11 minutes), are degraded very rapidly. See Thomas E Creighton (1993). “Chapter 10-Degradation”. Proteins: Structures and Molecular Properties (2nd ed.). WH Freeman and Company. pp.463-473. ISBN 0-7167-2317-4. In eukaryotes, most short-lived proteins in the intracellular space are degraded by the ubiquitin-proteasome pathway (UPP). See Kybuczkova L, et al. J Cell Mol Med. 2014. 18:947-961. UPPs play a central role in cellular homeostasis in protein processing and degradation, including those that regulate cell cycle progression, apoptosis, and DNA repair. See Heinemeyer W, et al. J Biol Chem. 1997. 272:25200-25209. Lysosomes also remove unwanted proteins from both the cytoplasm and extracellular space. Extracellular substances are taken up by endocytosis, and intracellular substances are digested by autophagy. See Settembre C, et al. Nature Reviews Molecular Cell Biology. 2013. 14(5):283-96. The half-life of GM-CSF has been shown to be as long as 50-85 minutes. See Cebon et al. Blood. 1988. 72:1340-1347; Stagg et al 2004. The in vivo biological activity of natural and recombinant GM-CSF is highly dependent on its bioavailability. See Dorr RT. Clinical Therapeutics / vol.15, NO.1, 1993.
[0016] The bioavailability of therapeutic proteins (biological agents or biologics) in humans can also be affected by the route of drug administration. See Dorr RT, Clinical Therapeutics / vol.15, NO.1, 1993. Immediately after intravenous (IV) administration, almost all therapeutic proteins are available, but thereafter they may be degraded over time by proteases present in the plasma. In some cases, subcutaneous (SC) administration can be better tolerated compared to IV administration by maintaining higher plasma concentrations for a longer period, thereby extending exposure to proteins with short elimination half-lives. Therefore, the absorption of biological agents after SC administration may be affected by their kinetics in the extracellular matrix (ECM), including the possibility of incomplete bioavailability. See Hale G, et al. Blood. 2004. 104(4):948-955.
[0017] Due to their differing molecular sizes, various pathways may be preferred for the transport of the various isoforms present in salglamostim into the systemic circulation. Two non-glycosylated rhu GM-CSF Leu23 types of salglamostim (approximately 14 kDa on SDS-PAGE gel, full-length molecule and cleaved Ala) 3 des-A 1 P 2 The molecular weights determined from the amino acid sequences of the species (14,430.47 and 14266.31) should clearly preferentially diffuse into capillaries, and therefore the bioavailability of these protein molecules in the bloodstream should be very rapid. Approximately eight O-glycosylated glycoforms containing 1 to 8 mannose sugar residues (approximately 16 kDa on SDS-PAGE gel, molecular weight measured by mass spectrometry: 14,500 to 16,000) may be delivered into the systemic circulation through both lymphatic vessels and capillaries. However, given their molecular size, the N- and N-+O-glycosylated glycoforms containing two n-acetylglucosamine residues and 6 to 27 mannose residues (approximately 21 kDa on SDS-PAGE gel, molecular weight measured by mass spectrometry: 16,200 to 19,000) are likely to be strongly preferred for diffusion and absorption via the lymphatic pathway.
[0018] GM-CSF expression systems may influence pharmacokinetic parameters, and the degree of glycosylation may affect the half-life, distribution, and excretion of GM-CSF. The relationship between the degree of glycosylation of GM-CSF and its distribution, clearance, and activity has been reported using rat models. In vitro measurements of GM-CSF specific activity have shown that the largest and most completely glycosylated protein form is significantly lower than that of smaller, less glycosylated molecules. The effective half-life of GM-CSF in rat bloodstream after a single intravenous bolus injection has been shown to be significantly prolonged by the addition of N-linked carbohydrates. GM-CSF clearance in rats follows a biphasic kinetic model, with carbohydrate modification extending either phase 1 or phase c~. See Donohue RE, et al. Cold Spring Harbor Labs. 1986. 51:685-692 and Dorr RT Clinical Therapeutics. 1993. 15(1):19-29.
[0019] Although the biological activity of the "highly glycosylated" rhu GM-CSF species has been shown to be statistically significantly lower, the specific activity (SA) of the 19.5, 16.8, and 15.5 kDa species is very similar. The SA of the other three glycoforms, N- and N-+O-glycosylated species (21 kDa, peak 2), O-glycosylated species (16 kDa, peak 3), and unglycosylated species (14 kDa, peak 4), has been shown to be statistically inconsistent with 99% confidence levels compared to the values obtained for the parent BDS, salglamostim.
[0020] There is still a need for GM-CSF molecules that can be purified using simple methods and contain very few "highly glycosylated" species. [Overview of the project]
[0021] Therefore, the present invention relates to mutant forms of GM-CSF, in particular mutant forms of GM-CSF that provide a unique glycoform profile compared to wild-type or sargramostim.
[0022] In various embodiments, it includes an amino acid sequence having at least about 97% identity with SEQ ID NO: 1 or SEQ ID NO: 2 and having a substitution or deletion at position N37, E38, and / or T39 or corresponding positions thereof. For example, the amino acid at position N37 or the corresponding position may be substituted with a polar and neutrally charged hydrophilic amino acid (such as glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C)); the amino acid at position E38 or the corresponding position may be substituted with a hydrophobic aliphatic amino acid (such as alanine (A), leucine (L), isoleucine (I), methionine (M), and valine (V) and not proline); and / or the amino acid at position T39 or the corresponding position may be substituted with alanine (A), glycine (G), leucine (L), isoleucine (I), methionine (M), and valine (V). A recombinant human GM-CSF protein is provided.
[0023] In various embodiments, the recombinant human GM-CSF of the present invention is functionally similar to sargramostim. In various embodiments, the recombinant human GM-CSF of the present invention includes multiple molecular forms, such as non-glycosylated form, O-glycosylated form, N-glycosylated form, and / or N+O glycosylated form. In various embodiments, the recombinant human GM-CSF of the present invention substantially does not contain highly glycosylated forms, such as high-mannosylated form. In various embodiments, the recombinant human GM-CSF of the present invention is separated as three peaks when quantified by reverse-phase high-performance liquid chromatography (RP-HPLC). In various embodiments, the recombinant human GM-CSF of the present invention does not provide a substantial peak with a retention time of less than about 20 minutes when quantified by reverse-phase high-performance liquid chromatography (RP-HPLC). In various embodiments, the recombinant human GM-CSF of the present invention substantially does not contain highly glycosylated forms, such as high-mannosylated form, when purified without using an organic solvent (such as, but not limited to, acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and / or a reverse-phase C4 HPLC column used for the purpose of purification and / or removal of highly glycosylated peaks.
[0024] In various embodiments, the recombinant human GM-CSF produced in mammalian cells is functionally enhanced compared to the recombinant human GM-CSF produced in yeast cells.
[0025] In various embodiments, the production titer of the recombinant human GM-CSF produced in mammalian cells increases compared to the production in yeast cells.
[0026] In some embodiments, nucleic acid molecules encoding the recombinant human GM-CSF of the present invention (e.g., codon-optimized sequences) are also provided. In some embodiments, non-human host cells expressing the nucleic acid molecules encoding the recombinant human GM-CSF of the present invention (e.g., yeast cells, e.g., non-methylotrope yeast cells, e.g., Saccharomyces cerevisiae) are also provided. Furthermore, in some embodiments, pharmaceutical compositions comprising the recombinant human GM-CSF of the present invention and pharmaceutically acceptable excipients or carriers are also provided.
[0027] In some embodiments, a method is provided for treating a patient or subject who is or has been treated for cancer, or who has undergone or has undergone a bone marrow transplant, and / or who has been acutely exposed to a bone marrow-suppressing dose of radiation, the method comprising administering a therapeutically effective amount of the pharmaceutical composition described herein to the patient.
[0028] In various embodiments, a method for treating a viral infection, such as an infection caused by a coronavirus, such as not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising administering an effective amount of the pharmaceutical composition described herein, or a method for treating or preventing a viral infection in a subject in need thereof, wherein the method comprises providing plasma from a donor subject who has recovered from a viral infection, such as an infection caused by a coronavirus, such as not limited to SARS-CoV-2, wherein the plasma comprises IgG, IgM, and / or IgA antibodies directed against the virus causing the infection, and the donor subject has been treated with recombinant human GM-CSF protein described herein to stimulate antibody production, and a method for treating or preventing a viral infection by providing and administering the plasma to a subject in need thereof.
[0029] In various embodiments, a method is provided for producing a recombinant that produces a composition comprising recombinant human GM-CSF, comprising: (a) obtaining an enzyme cell or extract thereof transfected with a nucleic acid encoding recombinant human GM-CSF having at least about 97% identity with SEQ ID NO: 2 and comprising an amino acid sequence having substitutions or deletions at the N37, G38, and / or T39 positions or corresponding positions; (b) purifying GM-CSF from the transfected yeast cells using one or more HPLC columns, wherein the purification is in the absence of organic solvents (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and / or a reversed-phase C4 HPLC column used for the purpose of purifying and / or removing high glycosylation peaks; and (c) collecting the purified GM-CSF, wherein the purified GM-CSF substantially does not contain high glycosylation, e.g., high-mannosylation GM-CSF forms. [Brief explanation of the drawing]
[0030] [Figure 1] This shows GM-CSF expressed in Saccharomyces as quantified by HPLC. Asterisks identify the highly mannosylated GM-CSF peak. [Figure 2] The Western blot used to confirm the identity of the protein is shown. [Figure 3] The reverse-phase HPLC assay used to determine the composition ratio of the rhu GM-CSF glycoform is shown. [Figure 4] This shows a comparison of chromatograms of BDS LEUKINE (reference standard) grown in yeast versus rhu GM-CSF expressed in CHO. BDS LEUKINE refers to the wild-type GM-CSF of SEQ ID NO: 1, which does not contain either the T39A or N37Q amino acid substitution in its sequence. [Figure 5]This shows a comparison of size exclusion chromatograms of BDS LEUKINE (reference standard) grown in yeast versus rhu GM-CSF expressed in CHO. [Figure 6] This shows the fermentation titer of rhu GM-CSF grown in yeast versus rhu GM-CSF grown in CHO cells. [Figure 7] This paper presents a comparison of functional TF-1 bioassays measuring the biological activity of rhu GM-CSF containing mutations T39A and N37Q, and LEUKINE (i.e., GM-CSF without T39A or N37Q). [Figure 8] This paper presents TF-1 assay data measuring the biological activity of rhu GM-CSF containing the mutant N37Q, grown in CHO cells, compared to three different batches of BDS LEUKINE stored under different conditions (a novel Leukine BDS substance, Leukine BDS stored at 2-8°C for 12 months, and Leukine stored at -70°C for 48 months). [Modes for carrying out the invention]
[0031] The present invention is partly based on the discovery that a single amino acid change in the sequence of salglamostim, for example at positions 37, 38, and / or 39 of salglamostim, or its equivalent, generates a functional GM-CSF that does not require purification by an organic solvent (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and / or reverse-phase C4 HPLC column used for the purpose of purifying and / or removing the high glycosylation peak observed in salglamostim.
[0032] Composition of GM-CSF In one embodiment, an engineered GM-CSF protein is provided.
[0033] In various embodiments, the manipulated GM-CSF used in carrying out the present invention includes any pharmaceutically safe and effective GM-CSF, or any derivative thereof having the biological activity of GM-CSF and any substitutions and / or deletions of the present invention.
[0034] In one embodiment, the manipulated GM-CSF used in carrying out the method of the present invention is derived from recombinant human GM-CSF (rhu GM-CSF) such as salglamostim (LEUKINE). Salglamostim is a recombinant human GM-CSF derived from biosynthesized yeast and has a single 127-amino acid glycoprotein that differs from endogenous human GM-CSF in that it has leucine instead of proline at position 23. Other natural and synthetic GM-CSFs, as well as their derivatives having the biological activity of natural human GM-CSF, may be equally useful in carrying out the present invention.
[0035] In some embodiments, the recombinant human GM-CSF molecule of the present invention is glycosylated. In some embodiments, the recombinant human GM-CSF molecule of the present invention contains one or more substitutions and / or deletions that affect the glycosylation of GM-CSF.
[0036] While we do not wish to be constrained by theory, the degree of glycosylation of biosynthesized GM-CSF is thought to affect its half-life, distribution, and excretion. (Lieschke and Burgess, N.Engl.J.Med.327:28-35,1992; Dorr, RT, Clin.Ther.15:19-29,1993; Horgaard et al., Eur.J.Hematol.50:32-36,1993).
[0037] In one embodiment, a recombinant human GM-CSF protein is provided that has at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% identity with SEQ ID NO: 1 or SEQ ID NO: 2, and comprises an amino acid sequence having substitutions or deletions at positions N37, E38, and / or T39 or corresponding positions.
[0038] In various embodiments, the amino acid at position N37 or the corresponding position of recombinant human GM-CSF is a polar and neutrally charged hydrophilic amino acid. In various embodiments, the polar and neutrally charged hydrophilic amino acid is selected from glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C). In various embodiments, the polar and neutrally charged hydrophilic amino acid is glutamine (Q).
[0039] In various embodiments, the amino acid at position E38 or the corresponding position of recombinant human GM-CSF is a hydrophobic aliphatic amino acid and / or not proline. In various embodiments, the hydrophobic aliphatic amino acid is selected from alanine (A), leucine (L), isoleucine (I), methionine (M), and valine (V).
[0040] In some embodiments, the amino acid at position T39 or the corresponding position of recombinant human GM-CSF is a hydrophobic aliphatic amino acid. In some embodiments, the hydrophobic aliphatic amino acid is selected from alanine (A), glycine (G), leucine (L), isoleucine (I), methionine (M), and valine (V). In some embodiments, the hydrophobic aliphatic amino acid is alanine (A). In some embodiments, the amino acid at position T39 or the corresponding position of recombinant human GM-CSF is uncharged. In some embodiments, the amino acid at position T39 or the corresponding position of recombinant human GM-CSF is not glutamic acid (E).
[0041] In various embodiments, recombinant human GM-CSF proteins are provided that have at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% identity with SEQ ID NO: 1 or SEQ ID NO: 2, and include an amino acid sequence having one or more of the following mutations: N37 deletion, N37Q, N37S, N37T, N37P, N37C, E38 deletion, E38A, E38L, E38I, E38M, E38V, T39 deletion, T39A, T39G, T39L, T39I, T39M, and T39V or the corresponding mutation.
[0042] In various embodiments, recombinant human GM-CSF has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or a variant having substitutions and / or deletions of the present invention with approximately 90%, 93%, 95%, 97%, or 98% identity thereto.
[0043] In various embodiments, GM-CSF is one of morphamostim, salglamostim, and reglamostim having substitutions and / or deletions of the present invention.
[0044] While we do not wish to be constrained by theory, the core of hGM-CSF consists of four angled, packed helices. Crystal structure and mutagenicity analysis of rhGM-CSF (Rozwarski DA et al., Proteins 26:304-13, 1996) revealed that, in addition to the nonpolar side chains of the protein core, 10 buried hydrogen-bonding residues intramolecularly hydrogen-bond to the main chain atoms, better conserved than residues hydrogen-bonding to other side chain atoms; 24 solvation sites were found at equivalent positions of two molecules within the asymmetric unit, the strongest of which were located at the cleavage between secondary structure elements. Two surface clusters of hydrophobic side chains are located near the expected receptor-binding region. Mutagenesis of residues on the helix A / helix C surface confirmed the importance of specific Glu, Gly, and Gln residues. Therefore, these residues are not substituted in the functional substitution variants of hGM-CSF used in the present invention, and these helices are retained in the functional fragments or deletion variants of hGM-CSF used in the present invention.
[0045] Furthermore, in various embodiments, those skilled in the art can refer to UniProtKB entry P04141 for structural information to indicate the identity of the variant.
[0046] The N-terminal helix of hGM-CSF governs its high-affinity binding to its receptor (Shanafelt AB et al., EMBO J 10:4105-12, 1991). The transmission of the biological effects of GM-CSF requires interaction with at least two cell surface receptor components (one of which is shared with the cytokine IL-5). The above study identified receptor-binding determinants within GM-CSF by locating unique receptor-binding domains on a series of human-mouse hybrid GM-CSF cytokines. The interaction between GM-CSF and the shared subunits of their high-affinity receptor complexes was governed by very small portions of the peptide chain. Several key residues present in the N-terminal α-helix were sufficient to confer specificity to the interaction.
[0047] Therefore, in various embodiments, this information can be made known to those skilled in the art regarding acceptable variations in the amino acid sequence.
[0048] In some embodiments, the amino acid mutation is an amino acid substitution, which may include conserved substitutions and / or non-conservative substitutions.
[0049] "Conservative substitutions" can be made, for example, based on similarities in the polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or amphiphilicity of the amino acid residues involved. The 20 native amino acids can be classified into the following six standard amino acid groups: (1) Hydrophobic: Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr; Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues affecting chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe.
[0050] As used herein, “conservative substitution” is defined as the exchange of an amino acid by another amino acid listed within the same group of the six standard amino acid groups described above. For example, the exchange of Asp by Glu retains one negative charge within the thus modified polypeptide. Furthermore, glycine and proline may be substituted for each other based on their ability to disrupt α-helices.
[0051] As used herein, “non-conservative substitution” is defined as the exchange of an amino acid by another amino acid listed in a different group from the six standard amino acid groups (1) to (6) above.
[0052] In various embodiments, substitutions may also include non-classical amino acids (e.g., selenocysteine, pyrrolicin, N-formylmethionine β-alanine, GABA and δ-aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers of common amino acids, 2,4-diaminobutyric acid, α-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, γ-Abu, ε-Ahx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosme, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoroamino acids, designer amino acids, e.g., β-methylamino acids, C-α-methylamino acids, N-α-methylamino acids, and common amino acid analogs).
[0053] Amino acid sequence modifications can be achieved using any known technique in the art, such as site-directed mutagenesis or PCR-based mutagenesis. Such techniques are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, 1989 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1989.
[0054] Glycoform In various embodiments, the recombinant human GM-CSF molecule of the present invention comprises multiple molecular forms. In various embodiments, the molecular form is selected from a non-glycosylated form, an O-glycosylated form, an N-glycosylated form, and an N+O glycosylated form.
[0055] In some embodiments, recombinant human GM-CSF is substantially free of highly glycosylated forms, such as highly mannosylated forms. In some embodiments, recombinant human GM-CSF has about 10% or less than 10% of highly mannosylated forms after purification, or about 5% or less than 5% of highly mannosylated forms after purification, or about 3% or less than 3% of highly mannosylated forms after purification, or about 2% or less than 2% of highly mannosylated forms after purification, or about 1% or less than 1% of highly mannosylated forms after purification.
[0056] In various embodiments, recombinant human GM-CSF exhibits fewer high-mannosylation morphs than wild-type human GM-CSF and / or salglamostim when expressed and purified in the same manner. In various embodiments, recombinant human GM-CSF exhibits approximately 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% fewer high-mannosylation morphs than wild-type human GM-CSF and / or salglamostim when expressed and purified in the same manner. In various embodiments, the amount of the highly mannosylated form can be detected as known in the art, for example, but not limited to, chromatography (e.g., by size separation (e.g., by molecular weight and / or retention time in a column) and / or by fluorescent labeling (e.g., anion exchange chromatography using 2-aminobenzoic acid (2-AA), 2-aminobenzamide (2-AB), and 2-aminopyridine (2-AP)), mass spectrometry, SDS-PAGE / staining (e.g., gel staining based on the periodic acid Schiff (PAS) reaction), affinity-based methods such as the use of glycosphingopropyl alcohol (lectins, etc.), enzyme-based methods, antibody-based methods, release assays (e.g., enzymatic cleavage or chemical removal of glycans, or chemical derivatization), capillary electrophoresis, and eastern blotting.
[0057] In various embodiments, the recombinant human GM-CSF of the present invention is suitable for purification that is less complex than that used in salglamostim.
[0058] In various embodiments, the mutant GM-CSF protein of the present invention is separated as three glycoforms, for example by HPLC, and lacks a highly glycosylated form. In comparison with Figure 1, which shows the four peaks of GM-CSF separated by HPLC, the asterisk identifies the highly mannosylated GM-CSF peak.
[0059] In various embodiments, the GM-CSF protein of the present invention can be purified without high glycosylated species, without the need for one or more organic solvents (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and / or a reversed-phase C4 HPLC column used for the purpose of purifying and / or removing high glycosylated peaks. In various embodiments, the GM-CSF protein of the present invention can be purified without high glycosylated species, without the use of acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol. In various embodiments, the GM-CSF protein of the present invention can be purified without a reversed-phase C4 HPLC column used for the purpose of purifying and / or removing high glycosylated peaks.
[0060] In some embodiments, the recombinant human GM-CSF of the present invention separates into three peaks when quantified by reverse-phase high-performance liquid chromatography (RP-HPLC). In some embodiments, the recombinant human GM-CSF does not provide substantial peaks with a retention time of less than approximately 20 minutes when quantified by reverse-phase high-performance liquid chromatography (RP-HPLC).
[0061] In various embodiments, the recombinant human GM-CSF of the present invention comprises two or more species (e.g., glycoforms). In various embodiments, no species with a molecular weight greater than approximately 20 kDa are present.
[0062] In various embodiments, recombinant human GM-CSF is substantially free of highly mannosylated forms when purified without the use of organic solvents (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and / or reverse-phase C4 HPLC columns used for the purpose of purifying and / or removing highly glycosylated peaks.
[0063] In various embodiments, recombinant human GM-CSF produced in mammalian cells such as Chinese hamster ovary (CHO) cells is a monomer having a heterogeneous glycoform that includes both glycosylated and non-glycosylated isoforms.
[0064] Functional characteristics of recombinant GM-CSF In various embodiments, recombinant human GM-CSF molecules of the present invention having substitutions and / or deletions of the present invention are functionally similar to wild-type human GM-CSF and / or salglamostim (for example, one or more functional parameters differ by about 50% or less, or about 40% or less, or about 30% or less, or about 20% or less, or about 10% or less, or about 5% or less, or about 5 times or less, or about 4 times or less, or about 3 times or less, or about 2 times or less of the assayed functional parameters). In various embodiments, the functional parameters of GM-CSF can be detected by assays known in the art, such as proliferation assays using cells such as TF-1 cell lines and primary bone marrow cells, biochemical assays such as ILITE(EAGLE)GM-CSF (luciferase under the control of a GM-CSF promoter), cell viability assays such as bone marrow cell viability assays, cell differentiation assays, and co-culture experiments.
[0065] In various embodiments, recombinant human GM-CSF molecules of the present invention having substitutions and / or deletions of the present invention bind to and / or activate granulocyte-macrophage colony-stimulating factor receptors (GM-CSF-R-α or CSF2R). In various embodiments, recombinant human GM-CSF molecules of the present invention having substitutions and / or deletions of the present invention bind to and / or activate granulocyte-macrophage colony-stimulating factor receptors (GM-CSF-R-α or CSF2R) with affinity, efficacy, and / or biological activity equivalent to wild-type human GM-CSF and / or salglamostim (for example, one or more functional parameters differ by about 50% or less, or about 40% or less, or about 30% or less, or about 20% or less, or about 10% or less, or about 5% or less, or about 5 times or less, or about 4 times or less, or about 3 times or less, or about 2 times or less). Assays relating to GM-CSF binding and activation are known in the art. Non-limiting examples of such assays include, for example, radioactive ligand assays or non-radioactive ligand assays (e.g., immunoprecipitation (IP), enzyme-linked immunosorbent assay (ELISA), Western blotting, fluorescence polarization (FP), fluorescence resonance energy transfer (FRET), surface plasmon resonance (SPR), and radioimmunoassay (RIA)). Binding dynamics can also be evaluated by standard assays known in the art, such as Biacore analysis. Whole-cell ligand binding assays and cell-free assay systems using soluble GM-CSF receptor α (sGMRa) may also be used. Several other types of assays that can be used include receptor binding assays, saturated binding assays, or competitive binding assays using radioactive iodized GM-CSF, and cell proliferation assays.
[0066] In various embodiments, the recombinant human GM-CSF molecule of the present invention can be assayed using one or more cell-based activity bioassays, for example, using a GM-CSF-dependent human cell line proliferation assay, such as TF-1, M-07e, HU-3, M-MOK, MB-02, GM / SO, F-36P, GF-D8, ELF-153, AML-193, MUTZ-3, OCI-AML5, OCI-AML6, OCI-AML1, SKNO-1, UCSD-AML1, and UT-7.
[0067] In various embodiments, the potency of the recombinant human GM-CSF molecule of the present invention is measured using a bioassay with TF-1 cells, a human erythroleukemia cell line that proliferates in response to GM-CSF. Details of this assay are known in the art. For example, a reference standard, control, and test sample are triple-diluted in assay medium and added to three separate 96-well plates. Then, TF-1 cells in suspension are added, and the mixture is incubated at 37°C for 69.5–72 hours. After adding a fluorescent dye (e.g., ALAMARBLUE), the plates are incubated at 37°C for 6.6–8 hours. Then, the proliferation of TF-1 cells is measured using a fluorescence microplate reader.
[0068] In various embodiments, the recombinant human GM-CSF molecule of the present invention has substantially the same specific activity as recombinant human GM-CSF lacking mutations (for example, assayed using a bioassay with TF-1 cells).
[0069] In various embodiments, recombinant human GM-CSF produced in mammalian cells, such as Chinese hamster ovary cells (CHO), is functionally enhanced compared to recombinant human GM-CSF produced in yeast cells.
[0070] In various embodiments, GM-CSF-R-α, which binds and / or is activated, is expressed on the surface of cells. In various embodiments, the cells are hematopoietic progenitor cells. In various embodiments, the hematopoietic progenitor cells are immune cells. In some embodiments, the hematopoietic progenitor cells are irradiated.
[0071] In various embodiments, the immunogenicity of recombinant human GM-CSF molecules of the present invention having substitutions and / or deletions of the present invention is equivalent to that of wild-type human GM-CSF and / or salglamostim (for example, one or more functional parameters differ by about 50% or less, or about 40% or less, or about 30% or less, or about 20% or less, or about 10% or less, or about 5% or less, or about 5 times or less, or about 4 times or less, or about 3 times or less, or about 2 times or less). In various embodiments, immunogenicity is assayed using methods known in the art. Non-limiting examples include, for example, screening assays, e.g., direct or indirect or cross-linked ELISA, electrochemiluminescence, bead-based chemiluminescence assays, radioimmunoprecipitation assays, surface plasma resonance, and biolayer interferometry, and detection of one or more anti-GM-CSF binding antibodies assayed by cell-based luciferase reporter gene neutralizing antibody assays.
[0072] In various embodiments, recombinant human GM-CSF is soluble.
[0073] Nucleic acids and host cells In various embodiments, nucleic acid molecules encoding recombinant human GM-CSF as described herein are provided. In various embodiments, the nucleic acid molecule has a codon-optimized sequence.
[0074] In various embodiments, non-human host cells expressing the nucleic acid molecules described herein are provided.
[0075] In various embodiments, the host cell is a yeast, mammal, bacterium, insect, algae, or plant cell.
[0076] In some embodiments, the yeast cells are non-methylotrope yeast cells. In some embodiments, the host cells are Saccharomyces cerevisiae cells.
[0077] In various embodiments, CHO cells expressing the nucleic acid molecules described herein are provided.
[0078] Pharmaceutical compositions and preparations In various embodiments, pharmaceutical compositions are provided that comprise recombinant human GM-CSF as described herein and a pharmaceutically acceptable excipient or carrier.
[0079] Any pharmaceutical composition described herein may be administered to a subject as a component of a composition comprising a pharmaceutically acceptable carrier or medium. Such a composition may optionally contain appropriate amounts of pharmaceutically acceptable excipients to provide a form for appropriate administration.
[0080] In various embodiments, the pharmaceutically acceptable excipients may be liquids such as water and oils, including oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Examples of pharmaceutically acceptable excipients include saline, acacia gum, gelatin, starch paste, talc, keratin, colloidal silica, and urea. In addition, auxiliary agents, stabilizers, thickeners, lubricants, and colorants may be used. In one embodiment, the pharmaceutically acceptable excipient is sterile when administered to the subject. Water is a useful excipient when any of the drugs described herein are administered intravenously. Saline and aqueous solutions of dextrose and glycerol may also be used as liquid excipients, particularly for injections. Other suitable pharmaceutically acceptable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, and ethanol. Any of the agents described herein may also contain small amounts of wetting or emulsifying agents or pH buffers, as needed. Other examples of suitable pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), which is incorporated herein by reference.
[0081] The present invention comprises the described pharmaceutical compositions (and / or additional therapeutic agents) in various formulations. Any of the pharmaceutical compositions (and / or additional therapeutic agents) of the present invention described herein may take the form of a liquid, suspension, emulsion, infusion, tablet, pill, pellet, capsule, liquid-containing capsule, gelatin capsule, powder, sustained-release formulation, suppository, emulsion, aerosol, spray, suspension, lyophilized powder, freeze-dried suspension, dry powder, or other form suitable for use. In one embodiment, the composition is in the form of a capsule. In another embodiment, the composition is in the form of a tablet. In yet another embodiment, the pharmaceutical composition is formulated in the form of a softgel capsule. In yet another embodiment, the pharmaceutical composition is formulated in the form of a gelatin capsule. In yet another embodiment, the pharmaceutical composition is formulated as a liquid.
[0082] If necessary, the pharmaceutical composition (and / or additional therapeutic agents) of the present invention may also contain a solubilizer. The drug may also be delivered using a suitable medium or delivery device known in the art. The combination therapies outlined herein may be co-delivered using a single delivery medium or delivery device.
[0083] Formulations comprising the pharmaceutical composition of the present invention (and / or additional therapeutic agents) may be conveniently provided in unit dosage forms and may be prepared by any method well known in the field of pharmaceuticals. Such methods generally involve the step of associating a therapeutic agent with a carrier constituting one or more minor components. Typically, formulations are prepared by homogeneously and closely associating a therapeutic agent with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, forming the product into the dosage form of the desired formulation (e.g., wet or dry granulation, powder blending, etc., and then tableting using conventional methods known in the art).
[0084] In various embodiments, any pharmaceutical composition (and / or additional therapeutic agent) described herein may be formulated in accordance with conventional procedures to be suitable for the dosage regimen described herein.
[0085] Routes of administration include, for example, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intranasal, intracerebral, vaginal, transdermal, rectal, inhalation, or topical. Administration may be topical or systemic. In some embodiments, administration is performed orally. In other embodiments, administration is performed by parenteral injection. The mode of administration is left to the discretion of the practitioner and varies to some extent depending on the site of the injury. In most cases, administration releases any of the drugs described herein into the bloodstream.
[0086] In certain embodiments, GM-CSF (and / or additional therapeutic agents) are administered via an intravenous route.
[0087] In one embodiment, the pharmaceutical compositions (and / or additional therapeutic agents) described herein are formulated as compositions suitable for oral administration by conventional procedures. Compositions for oral delivery may be, for example, in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. A composition for oral administration may contain one or more agents, such as sweeteners (e.g., fructose, aspartame, or saccharin); flavoring agents (e.g., peppermint, wintergreen oil, or cherry); colorants; and preservatives, providing a pharmaceutically palatable preparation. Furthermore, in the form of tablets or pills, the composition may be coated to slow disintegration and absorption in the gastrointestinal tract, thereby providing a sustained effect over a longer period. A selectively permeable membrane surrounding any osmotically active pharmaceutical composition (and / or additional therapeutic agent) described herein may also be suitable for a composition for oral administration. In these latter platforms, fluid from the environment surrounding the capsule is absorbed by the driving compound, which expands to displace the drug or drug composition from the opening. These delivery platforms can provide an essentially zero-order delivery profile, in contrast to the spike-like profile of immediate-release formulations. Time-delay materials such as glycerol monostearate or glycerol stearate may also be useful. The oral composition may contain standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are pharmaceutical grade. In addition to the active compound, the suspension may contain suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth, and mixtures thereof.
[0088] Suitable dosage forms for parenteral administration (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous, and intra-articular injection and infusion) include, for example, solutions, suspensions, dispersions, and emulsions. These can also be manufactured in the form of sterile solid compositions (e.g., lyophilized compositions) that can be dissolved or suspended in a sterile injection medium immediately before use. These may include, for example, suspensions or dispersants known in the art. Suitable formulation components for parenteral administration include sterile diluents, such as sterile water for injection, physiological saline, non-volatile oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as EDTA; buffering agents, such as acetates, citrates, or phosphates; and osmotic regulators, such as sodium chloride or dextrose.
[0089] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). The carrier must be stable under manufacturing and storage conditions and protected from microorganisms. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), or suitable mixtures thereof.
[0090] Any pharmaceutical composition (and / or additional therapeutic agent) of the present invention described herein may also be administered by controlled-release or sustained-release means or by delivery devices well known to those skilled in the art. Examples include, but are not limited to, those described in U.S. Patents No. 3,845,770, No. 3,916,899, No. 3,536,809, No. 3,598,123, No. 4,008,719, No. 5,674,533, No. 5,059,595, No. 5,591,767, No. 5,120,548, No. 5,073,543, No. 5,639,476, No. 5,354,556, and No. 5,733,556, each of which is incorporated herein by reference in whole. Such dosage forms may be useful for providing controlled or sustained release of one or more active ingredients, for example, by using hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof, to provide desired release profiles in various proportions. Suitable controlled-release or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the drugs described herein. For this purpose, the present invention provides single unit dosage forms suitable for oral administration, such as tablets, capsules, gel caps, and caplets, adapted for controlled or sustained release.
[0091] The controlled or sustained release of the active ingredient can be stimulated by a variety of conditions, including but not limited to changes in pH, changes in temperature, stimulation by light of an appropriate wavelength, enzyme concentration or availability, water concentration or availability, or other physiological conditions or compounds.
[0092] In another embodiment, the controlled-release system may be positioned near the target area being treated and therefore require only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, ibid., vol.2, pp.115-138 (1984)). Other controlled-release systems may be used, as discussed in the review by Langer, 1990, Science 249:1527-1533).
[0093] Pharmaceutical preparations are preferably sterile. Sterilization can be achieved, for example, by filtration through a sterile filter membrane. If the composition is freeze-dried, filter sterilization can be performed before or after freeze-drying and reconstitution.
[0094] Pharmacopoeia-acceptable salts and excipients The compositions described herein may possess sufficiently basic functional groups that can react with inorganic or organic acids or carboxyl groups, and with inorganic or organic bases to form pharmaceutically acceptable salts. As is well known in the art, pharmaceutically acceptable acid addition salts are formed from pharmaceutically acceptable acids. Such salts include, for example, the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. PHStahl and CGWermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are incorporated herein by reference in their entirety.
[0095] Pharmaceutically acceptable salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acidic phosphates, isonicotinates, lactates, salicylates, acidic citrates, tartrates, oleates, tannates, pantothenates, hydrogen tartrates, ascorbic acid, succinates, maleates, gentisinates, fumarates, glucons, glucarones, saccharates, formates, benzoates, glutamates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, camphorsulfons, pamoates, phenylacetates, trifluoroacetates, acrylates, chlorobenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, methyl benzoates, Examples include o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, α-hydroxybutyrate, butyn-1,4-dicarboxylate, hexyn-1,4-dicarboxylate, caprine, caprylate, cinnamate, glycolate, heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate, phenyl propionate, sebacinate, suberinate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, xylenesulfonate, and tartrate.
[0096] The term "pharmaceutically acceptable salt" also refers to salts of the compositions of the present invention having acidic functional groups such as carboxylic acid functional groups and bases. Suitable bases include, but are not limited to, alkali metal hydroxides such as sodium, potassium, and lithium; alkaline earth metal hydroxides such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia, and organic amines such as unsubstituted or hydroxysubstituted mono-, di-, or tri-alkylamines and dicyclohexylamines; tributylamine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tri-(2-OH-lower alkylamines) such as mono-, bis-, or tris-(2-hydroxyethyl)amine; N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine and lysine.
[0097] In some embodiments, the compositions described herein are in the form of pharmaceutically acceptable salts.
[0098] How to use In one embodiment, a method is provided for treating a patient or subject who is or has been receiving cancer treatment, or who has undergone or has undergone a bone marrow transplant, and / or has been acutely exposed to a bone marrow-suppressing dose of radiation, comprising administering a therapeutically effective amount of the recombinant human GM-CSF protein of the present invention or a pharmaceutically effective composition thereof to the patient. In various embodiments, the patient is treated by modulating the clonal proliferation, survival, differentiation, and activation state of hematopoietic progenitor cells. In various embodiments, the patient is treated by modulating the bone marrow monocyte cell lineage by promoting the proliferation of megakaryocyte and erythroid progenitor cells. In various embodiments, the patient is treated by modulating hematopoietic progenitor cells by stimulating the survival, proliferation, and activation of neutrophils, macrophages, and / or dendritic cells. In various embodiments, the patient is treated after a bone marrow transplant by modulating hematopoietic progenitor cells by stimulating the survival, proliferation, and activation of neutrophils, macrophages, and / or dendritic cells.
[0099] In one embodiment, a therapeutic method is provided comprising administering a therapeutically effective amount of the recombinant human GM-CSF protein of the present invention or a pharmaceutically effective composition thereof to a patient, or contacting cells with a therapeutically effective amount of the pharmaceutically effective composition thereof and administering cells, wherein the treatment promotes neutrophil recovery after induction chemotherapy and / or reduces the incidence of infection; recruits hematopoietic progenitor cells into the peripheral blood for harvesting by leukocyte apheresis and transplantation; promotes bone marrow reconstitution after transplantation of autologous or allogeneic bone marrow or peripheral blood progenitor cells; treats delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation; and / or treats hematopoietic syndrome of acute radiation syndrome (H-ARS).
[0100] In one embodiment, a method for treating a viral infection is provided, comprising administering an effective amount of a composition containing the recombinant human GM-CSF protein of the present invention or a pharmaceutical composition containing the same to a patient in need.
[0101] In various embodiments, the viral infection is an influenza infection arbitrarily selected from influenza A, B, C, and D type virus infections.
[0102] In some embodiments, the viral infection is a coronavirus infection. In some embodiments, the coronavirus is a betacoronavirus optionally selected from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), HCoV-HKU1, and HCoV-OC43. In some embodiments, the coronavirus is an alphacoronavirus optionally selected from HCoV-NL63 and HCoV-229E.
[0103] Coronaviruses belong to the family Coronaviridae, which includes beta-coronaviruses and alpha-coronaviruses, respiratory pathogens that have only recently become known to invade humans. The Coronaviridae family includes beta-coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), HCoV-HKU1, and HCoV-OC43. Alpha-coronaviruses include, for example, HCoV-NL63 and HCoV-229E.
[0104] Coronaviruses enter host cells via a "spike" surface glycoprotein that facilitates viral entry into the host cell by angiotensin-converting enzyme 2 (ACE2), a transmembrane receptor in mammalian hosts. (Zhou et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.)
[0105] COVID-19, caused by SARS-CoV-2, is a novel virus thought to have originated in bats. COVID-19 causes severe respiratory distress, and this RNA virus strain poses a significant threat to public health, responsible for the recent outbreak that has been declared a global emergency. Phylogenetic analysis of the SARS-CoV-2 genome revealed that this virus is most closely related to the SARS-like coronavirus group (Betacoronavirus genus, Sarbecovirus subgenus) (nucleotide similarity 89.1%). (Wu et al., A new coronavirus associated with human respiratory disease in China. Nature, Feb 3, 2020.)
[0106] SARS-CoV-2 is an enveloped single-stranded RNA virus that encodes the "spike" protein, also known as the S protein, a surface glycoprotein that mediates binding to cell surface receptors, as well as an intrinsic membrane protein, an envelope protein, and a nucleocapsid protein. The S protein, including the S1 and S2 subunits, is a trimer class I fusion protein that exists in the prefusion conformation, undergoing structural rearrangement to fuse the viral membrane with the host cell membrane. See, for example, Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3:237-261 (2016). This document is incorporated herein by reference in its entirety. The structure of the SARS-CoV-2 spike protein in the prefusion conformation has been previously discovered. See Daniel et al., Cryo-EM structure of the SARS-CoV-2 spike in the prefusion conformation. Science, 19 Feb 2020. This document is incorporated in its entirety herein by reference.
[0107] Phylogenetic analysis of the entire genome of SARS-CoV-2 (GenBank accession number: MN908947) revealed that this virus is most closely related to the SARS-like coronavirus group (Betacoronavirus genus, Sarbecovirus subgenus) (nucleotide similarity 89.1%). Wu et al., A new coronavirus associated with human respiratory disease in China. Nature, Feb 3, 2020 (This document is incorporated herein by reference in its entirety).
[0108] SARS-CoV-2 possesses a spike surface glycoprotein, membrane glycoprotein M, envelope protein E, and nucleocapsid phosphorylated protein N. The entire genome (29,903 nucleotides, single-stranded RNA) of the SARS-CoV-2 coronavirus is listed in the NCBI database as GenBank reference sequence: MN908947. Coronavirus proteins can be selected from the following group: coronavirus spike protein (GenBank reference sequence: QHD43416), coronavirus membrane glycoprotein M (GenBank reference sequence: QHD43419), coronavirus envelope protein E (GenBank reference sequence: QHD43418), and coronavirus nucleocapsid phosphorylated protein E (GenBank reference sequence: QHD43423).
[0109] In various embodiments, this method prevents or alleviates the onset of acute respiratory distress syndrome (ARDS) in patients.
[0110] In some embodiments, the coronavirus is SARS-CoV-2. In some embodiments, the patient has COVID-19. In some embodiments, the patient suffers from one or more of the following: fever, cough, shortness of breath, diarrhea, upper respiratory tract symptoms, lower respiratory tract symptoms, pneumonia, and acute respiratory syndrome.
[0111] In various embodiments, the patient is hypoxic. In various embodiments, the patient is suffering from respiratory distress. In various embodiments, the method improves the patient's oxygenation. In various embodiments, the method prevents or mitigates the transition from respiratory distress to cytokine imbalance in the patient. In various embodiments, the method reverses or prevents a cytokine storm. In various embodiments, the method reverses or prevents a pulmonary or systemic cytokine storm. In various embodiments, the cytokine storm is selected from one or more of systemic inflammatory response syndromes, cytokine release syndromes, macrophage activation syndromes, and hemophagocytic lymphohistiocytosis. In various embodiments, the method reverses or prevents the overproduction of one or more inflammatory cytokines. In various embodiments, the inflammatory cytokine is one or more of IL-6, IL-1, IL-1 receptor antagonist (IL-1ra), IL-2ra, IL-10, IL-18, TNFα, interferon-γ, CXCL10, and CCL7.
[0112] In various embodiments, this method reduces the viral load in patients compared to before treatment.
[0113] In one embodiment, a method is provided for treating or preventing a viral infection in a subject in need, the method comprising: providing plasma from a donor subject who has recovered from a viral infection, wherein the plasma contains IgG, IgM, and / or IgA antibodies directed against the virus causing the infection, and the donor subject has been treated with the recombinant human GM-CSF protein described herein to stimulate antibody production; and administering the plasma to a subject in need. In one embodiment, a method is provided for treating or preventing a viral infection in a subject in need, the method comprising: administering the recombinant human GM-CSF protein described herein to a donor subject who has recovered from a viral infection; isolating plasma from the donor subject containing IgG, IgM, and / or IgA antibodies directed against the virus causing the infection; and administering the plasma to a subject in need.
[0114] In various embodiments, such methods provide passive immunity to a virus to a target that requires it.
[0115] In various embodiments, IgG, IgM, and / or IgA antibodies specifically bind to viral antigens. In various embodiments, IgG, IgM, and / or IgA antibodies neutralize viruses. In various embodiments, IgG, IgM, and / or IgA antibodies prevent or reduce viral infection of cells.
[0116] In some embodiments, the viral infection is selected from betacoronavirus infections optionally selected from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), HCoV-HKU1, and HCoV-OC43 infections. In some embodiments, the viral infection is selected from alphacoronavirus infections optionally selected from HCoV-NL63 and HCoV-229E infections.
[0117] In various embodiments, beta-coronavirus infection is severe acute respiratory syndrome (SARS).
[0118] In various embodiments, the beta-coronavirus infection is either coronavirus infection 2019 (COVID-19) or related thereto.
[0119] In various embodiments, the viral infection is an influenza infection arbitrarily selected from influenza A, B, C, and D virus infections. In various embodiments, the influenza infection is pandemic influenza A(H1N1) or avian influenza A(H5N1).
[0120] In some embodiments, the donor subject is tested for positive for viral infection prior to recovery. In some embodiments, the donor subject has recovered from viral infection before donor provision. In some embodiments, the donor subject is tested for positive for antibodies directed against the virus using serological testing. In some embodiments, the donor subject exhibits a measurable neutralizing antibody titer. In some embodiments, the neutralizing antibody titer is at least about 1:160. In some embodiments, plasma is isolated from a blood sample from the donor subject. In some embodiments, plasma is isolated by plasmapheresis. In some embodiments, the plasma contains therapeutically effective amounts of IgG, IgM, and / or IgA antibodies directed against the virus causing the infection.
[0121] Combination therapy and additional treatments In various embodiments, the pharmaceutical compositions of the present invention are administered in combination with additional drugs(s). This combination administration may be simultaneous or sequential.
[0122] In one embodiment, the additional therapeutic agent and GM-CSF of the present invention are administered simultaneously to a subject. As used herein, the term “simultaneously” means that the additional therapeutic agent and GM-CSF are administered at time intervals of about 60 minutes or less, for example, about 30 minutes or less, about 20 minutes or less, about 10 minutes or less, about 5 minutes or less, or about 1 minute or less. The administration of the additional therapeutic agent and GM-CSF may be by simultaneous administration of a single formulation (e.g., a formulation comprising the additional therapeutic agent and the GM-CSF composition) or separate formulations (e.g., a first formulation comprising the additional therapeutic agent and a second formulation comprising the GM-CSF composition).
[0123] Concomitant administration does not require simultaneous administration of the drugs if the pharmacological activities of the additional drug and GM-CSF overlap in time, thereby producing a concomitant therapeutic effect. For example, the additional drug and the targeting moiety, and the GM-CSF composition can be administered sequentially. As used herein, the term “sequentially” means that the additional drug and GM-CSF are administered at time intervals of more than approximately 60 minutes. For example, the time between sequential administration of the additional drug and GM-CSF may be more than approximately 60 minutes, more than approximately 2 hours, more than approximately 5 hours, more than approximately 10 hours, more than approximately 1 day, more than approximately 2 days, more than approximately 3 days, more than approximately 1 week, more than approximately 2 weeks, or more than approximately 1 month. The optimal administration time depends on the metabolic rate, excretion rate, and / or pharmacodynamic activity rate of the additional drug and GM-CSF being administered. Either the additional drug or the GM-CSF composition may be administered first.
[0124] Concomitant administration does not require the therapeutic agents to be administered to the subject via the same route of administration. Rather, each therapeutic agent can be administered via any suitable route, such as parenteral or non-parenteral.
[0125] In some embodiments, the GM-CSF described herein acts synergistically when administered in combination with another therapeutic agent. In such embodiments, the targeted portion, the GM-CSF composition, and the additional therapeutic agent may be administered at lower doses than those used when the agent is used in conjunction with monotherapy.
[0126] In some embodiments, the additional therapeutic agent is an antiviral drug.
[0127] In some embodiments, additional therapeutic agents include antiviral drugs such as remdesivir, favipiravir, oseltamivir, baloxavir, galidesivir, amprenavir, tipranavir, saquinavir, nelfinavir, indinavir, darunavir, atazanavir, emetine, lopinavir and / or ritonavir, arbidol and lopinavir / ritonavir, and / or ribavirin, darunavir and cobicistat, and / or IFN-β-1b, β-D-N4-hydroxycytidine (NHC), such as EIDD-1931 or EIDD-2801 or EIDD-2801; immunomodulatory agents such as glucocorticoids, IFN-α2a, IFN-α 2b, IFN-b, pegylated IFN-g, baricitinib, sirolimus, crazakizumab, canakinumab, XPro1595, tocilizumab, sarilumab, siltuximab, adalimumab, eculizumab, ivermectin, anakinra, prezcobix, xiyanping, fingolimod, methylprednisolone, leronlimab, thalidomide, MK-2206, nicolasamide, nitazoxamide, chloroquine, or hydroxychloroquine; antibiotics, e.g., kalimab The drugs are selected from among those including isine, brilacidine, azithromycin, valinomycin, vasodilator / antagonists such as rhACE2 / GSK2586881 / APN01, losartan, eprosartan, telmisartan, valsartan, etc.; serine protease inhibitors such as camostat mesylate, nafamostat, etc.; and other drugs such as bromhexine, aprotinin, chlorpromazine, zotatifin, methotrexate, lenalidomide, anti-VEGF-A, and intravenous immunoglobulin (IVIG). For example, in various embodiments, any of these additional therapeutic agents are used in the context of SARS-CoV-2 infection.
[0128] In some embodiments, additional therapeutic agents are selected from favipiravir, laninamivir octanoate, peramivir, zanamivir, oseltamivir phosphate, baloxavir marboxil, umifenovir, urmin, amantadine hydrochloride, rimantadine hydrochloride, adapromin, LASAG / BAY81-87981, celecoxib, etanercept, metformin, gemcitabine, dapivine, trametinib, lisinopril, naproxen, nalidixic acid, dorzolamide, ruxolitinib, midodrine, diltiazem; statins, e.g., atorvastatin, nitazoxanide; and PPAR antagonists, e.g., gemfibrozil. For example, in various embodiments, any of these additional therapeutic agents are used in the context of influenza infection.
[0129] Manufacturing method In various embodiments, a method is provided for producing a recombinant that produces a composition comprising recombinant human GM-CSF, comprising: (a) obtaining cells or an extract thereof transfected with a nucleic acid encoding recombinant human GM-CSF having at least about 90%, at least about 93%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% identity with SEQ ID NO: 1 or SEQ ID NO: 2, and comprising an amino acid sequence having substitutions or deletions at the N37, G38, and / or T39 positions or the corresponding positions as described herein; (b) purifying GM-CSF from transfected yeast cells using one or more HPLC columns, wherein the purification is performed in the absence of organic solvents (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol); and (c) collecting the purified GM-CSF, wherein the purified GM-CSF substantially does not contain high glycosylated, e.g., high mannosylated GM-CSF forms.
[0130] In various embodiments, the cells are prokaryotic host cells or eukaryotic host cells, such as yeast, mammalian, bacterial, insect, algae, or plant cells.
[0131] Suitable prokaryotic host cells include bacterial cells (e.g., E. coli, Bacillus subtilis, Mycobacterium species, M. tuberculosis, or other suitable bacterial cells) and archaeal cells (e.g., Methanococcus jannaschii and Methanococcus maripaludis).
[0132] In some embodiments, the host cells of this disclosure are eukaryotic host cells. Suitable eukaryotic host cells include, but are not limited to, fungal cells, algal cells, insect cells, animal cells (e.g., mammalian cells, avian cells, and fish cells), and plant cells.
[0133] Suitable fungal host cells include, but are not limited to, Ascomycota, Basidiomycota, Deuteromycota, Zygomycota, and Fungi imperfecti.
[0134] Suitable yeast host cells include, but are not limited to, Candida, Hansenula, Saccharomyces, Schizosaccharomyces, Kluyveromyces, and Yarrowia. In some embodiments, the yeast cells are Hansenula polymorpha, Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Saccharomyces diastaticus, Saccharomyces norbensis, Saccharomyces kluyveri, Schizosaccharomyces pombe, Kluyveromyces lactis, Candida albicans, or Yarrowia lipolytica.
[0135] Suitable filamentous fungal host cells include, for example, any filamentous form of Eumycotina and Oomycota. In embodiments, the filamentous fungal host cells include Achlya, Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Cephalosporium, Chrysosporium, Cochliobolus, Corynascus, Cryphonectria, Cryptococcus, Coprinus, Coriolus, Diplodia, Endothis, Fusarium, Gibberella, Gliocladium, Humicola, Hypocrea, and Myceliophthora (for example, Myceliophthora). The cells may be those of species such as A. thermophila, Mucor, Neurospora, Penicillium, Podospora, Phlebia, Piromyces, Pyricularia, Rhizomucor, Rhizopus, Schizophyllum, Scytalidium, Sporotrichum, Talaromyces, Thermoascus, Thielavia, Tramates, Tolypocladium, Trichoderma, Verticillium, Volvariella, or their teleomorphs or anamorphs, and synonyms or taxonomic equivalents. In one embodiment, the filamentous fungus is selected from the group consisting of A. nidulans, A. oryzae, A. sojae, and Aspergilli of the A. niger group. In one embodiment, the filamentous fungus is Aspergillus niger.
[0136] In various embodiments, the cells are yeast cells, such as, but are not limited to, Saccharomyces cerevisiae.
[0137] In various embodiments, the cells are mammalian cells, such as, but not limited to, Chinese hamster ovary (CHO) cells.
[0138] In various embodiments, the production of recombinant proteins in mammalian cells increases the expression level of recombinant proteins compared to production using non-mammalian cells.
[0139] In some embodiments, the method further includes formulating purified GM-CSF for injection, such as subcutaneous or intravenous injection.
[0140] array Sequence ID No. 1 is wild-type GM-CSF. The deletion site of the present invention is indicated by an underline and bold.
[0141] [ka]
[0142] Sequence ID No. 2 is salglamostim. The deletion site of the present invention is indicated by an underline and bold.
[0143] [ka]
[0144] definition The following definitions are used in connection with the inventions disclosed herein. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the inventions pertain.
[0145] When used in relation to drugs effective in treating coronavirus infection, "effective dose" refers to the amount effective in treating or alleviating coronavirus infection.
[0146] As used herein, “a,” “an,” or “the” may mean one or more. Furthermore, when used in relation to a numerical value mentioned, the term “about” means adding or subtracting up to 10% of that numerical value. For example, the phrase “about 50” encompasses the range from 45 to 55.
[0147] Where used herein, all compositional percentages refer to the total weight of the composition unless otherwise specified. Where used herein, the word “include” and its variations are intended to be non-limiting so that the listing of items in the list does not exclude other similar items which may also be useful in the materials, compositions, devices, and methods of the Art. Similarly, the terms “may” and “may” and their variations are intended to be non-limiting so that a statement that an embodiment may include or may include a particular element or feature does not exclude other embodiments of the Art which do not include such element or feature.
[0148] The non-restrictive term “comprising,” as a synonym for terms such as “including,” “containing,” or “having,” is used herein to describe and claim the invention; however, the invention or its embodiments may be described using alternative terms such as “consisting of” or “essentially consisting of.”
[0149] The present invention can be further described by the following non-limiting embodiments. [Examples]
[0150] Example 1: Cloning and purification of GM-CSF mutants Regardless of the presence or absence of the mutations of the present invention, the fermentation and processing of the protein GM-CSF product were carried out in the absence of organic solvents used to remove the high glycosylation peak (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol), and / or reverse-phase C4 HPLC columns used for the purpose of purifying and / or removing the high glycosylation peak.
[0151] Importantly, organic solvents and reversed-phase C4 HPLC are used to produce GM-CSF lacking the mutations of the present invention, for example, to remove large high-glycosylation peaks from three glycoforms (see Figure 1). Since such organic solvents are not used in the mutants described herein, there is no need to use reversed-phase C4 HPLC intended to remove these organic solvents.
[0152] Example 2: Biochemical assay of GM-CSF mutants The biochemical identity of rhu GM-CSF was confirmed by Coomassie-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blotting (Figure 2). Purified rhu GM-CSF protein samples were diluted in Tris-glycine SDS sample buffer. The diluted rhu GM-CSF samples and reference standards were denatured by heating in a heat block at 100°C for 5 minutes. The reference standards and rhu GM-CSF samples were loaded onto precast 20% SDS-PAGE gels along with molecular weight markers. The loaded gels were subjected to electrophoresis at a constant voltage to separate the proteins, and then incubated in Coomassie G-250 stain to visualize the proteins. Rhu GM-CSF moved as three bands on SDS-PAGE. The supernatant was subjected to SDS-PAGE (4 ug / lane) and compared with the molecular weight ladder and reference standard.
[0153] Western blot analysis was performed to confirm protein identity (Figure 2). The purified rhu GM-CSF protein sample and reference standard were prepared for SDS-PAGE as described above. The reference standard and rhu GM-CSF sample were loaded onto a precast 20% SDS-PAGE gel along with a stained molecular weight marker. The loaded gel was subjected to electrophoresis at a constant voltage to separate the proteins, and then the proteins were transferred from the gel to a nitrocellulose membrane. The nitrocellulose membrane was then blotted with mouse anti-human GM-CSF monoclonal antibody, followed by blotting with alkaline phosphatase-bound goat anti-mouse IgG for immunodetection. The bands were visualized using alkaline phosphatase-developed solution. All supernatants were positive for GM-CSF based on the blot results (a positive band was present in the GM-CSF region compared to the reference standard) (Figure 2).
[0154] The composition ratio of rhu GM-CSF glycoforms was determined using reversed-phase HPLC (Figure 3). No organic solvents or reversed-phase C4 HPLC columns were used. Single-point mutants T39A (alanine substitution of threonine at position 39) and N37Q (glutamine substitution of asparagine at position 37) were tested using reversed-phase HPLC assays to determine their titer and glycoform. The titer (mg / ml) was calculated using a calibration curve prepared from a reference standard. This procedure divided the rhu GM-CSF glycosylated variants into three major glycoform groups. The results for the rhu GM-CSF concentrations in the test samples were interpolated from a 6-level external standard calibration curve prepared from the GM-CSF reference standard. The four peaks of interest were merged and quantified. Their respective compositions are shown below: Peak 1 = GM-CSF related impurities (oxidation) Peak 2 = N- and (N+O) bonded glycoforms Peak 3 = O-linked glycoform Peak 4 = Non-glycosylated GM-CSF This assay separated residual process components and hyperglycosylates from the product peaks to obtain glycoform profiles (peaks 2-4). Product peaks were reported normalized to exclude hyperglycosylates. T39A had approximately 6% hyperglycosylation, and N37Q had approximately 6.6%. Both samples had lower hyperglycosylation rates than the unmutated GM-CSF (approximately 40%, see Figure 1). Hyperglycosylates are typically removed by chromatography using organic solvents (e.g., but not limited to acetonitrile, trifluoroacetic acid (TFA), pyridine, acetic acid, and / or N-propanol) and reverse-phase C4 HPLC columns used for purification purposes. The variants of the present invention are particularly interesting because they may allow for the elimination of process steps, thereby saving time and resources and reducing the use of hazardous solvents in the purification process.
[0155] Reverse-phase HPLC was also used to determine the GM-CSF glycoform of BDS LEUKINE compared with mutant GM-CSF expressed in CHO cells (Figure 4). Size exclusion chromatography was also used to determine the molar mass distribution (Figure 5). Single-point mutant N37Q (glutamine substitution of asparagine at position 37) and BDS LEUKINE were tested using reverse-phase HPLC assays and SEC analysis to determine titer (Figure 6) and glycoform (Figures 4 and 5). BDS LEUKINE was produced using yeast cells, Saccromyces, and mutant GM-CSF was produced using mammalian CHO cells. This assay calculated titer (mg / ml) using a calibration curve prepared from a reference standard. This procedure divided the rhu GM-CSF glycosylated variants into three major glycoform groups. The results for the concentration of test samples rhu GM-CSF were interpolated from a 6-level external standard calibration curve prepared from GM-CSF reference standards. Similar to BDS LEUKINE, the mutant GM-CSF expressed in CHO cells was monomeric (Figure 5), and both samples exhibited multiple glycoforms (Figure 4). Production in CHO cells increased the titer of the recombinant protein compared to production in yeast (Figure 6). BDS LEUKINE refers to the wild-type GM-CSF of SEQ ID NO: 1, which does not contain either the T39A or N37Q amino acid substitution in its sequence.
[0156] Example 3: Functional assay of GM-CSF mutants The potency of rhu GM-CSF was measured using a bioassay with TF-1 cells, a human erythroleukemia cell line that proliferates in response to GM-CSF (Figure 7). Reference standard (rhu GM-CSF), control, and test samples were triple-diluted in assay medium and added to three separate 96-well plates. TF-1 cells in suspension were then added, and the mixture was incubated at 37°C for 69.5–72 hours. After adding fluorescent dyes (ALAMARBLUE, THERMO), the plates were incubated at 37°C for 6.6–8 hours. TF-1 cell proliferation was then measured using a fluorescence microplate reader. Single-point T39A and N37Q mutations, as well as GM-CSF without T39A or N37Q mutations (LEUKINE), were tested using the TF-1 bioassay. Specific activity (SA) in international units per milligram (IU / mg) was calculated from a standard curve using the reference standard (Salglamostim-rhuGM-CSF). Both mutants exhibited similar activity to LEUKINE, with SA showing 8.14 × 10⁶ activity compared to LEUKINE. 6 Compared to IU / mg, 9.13 × 10 6 (T39A) and 7.48×10 6 It was calculated to be (N37Q). [Table 1]
[0157] Surprisingly, these amino acid substitutions, despite being dramatic (for example, T39A significantly reduces side chain length, while N37Q increases it), make manufacturing easier without affecting biological activity.
[0158] Furthermore, the potency of the mutant rhu GM-CSF was measured using a bioassay with TF-1 cells, a human erythroleukemia cell line that proliferates in response to GM-CSF. Mutant rhu GM-CSF, which has a single amino acid at the N37 position and was grown in CHO cells, significantly enhanced the activity of the recombinant protein compared to three different batches of BDS LEUKINE grown in yeast cells (Saccromyces) under different conditions (Leukine BDS novel material, Leukine BDS stored at 2–8°C for 12 months, and Leukine stored at -70°C for 48 months) (Figure 8). BDS LEUKINE refers to the wild-type GM-CSF of SEQ ID NO: 1, which does not contain either the T39A or N37Q amino acid substitution in its sequence.
[0159] Equivalents Those skilled in the art will be able to recognize or confirm, by mere routine experimentation, many equivalents to the specific embodiments described herein in detail. Such equivalents are intended to be covered within the scope of the following claims.
[0160] Built-in by reference All patents and publications referenced herein are incorporated herein in their entirety by reference.
[0161] Where used herein, all headings are for structural reasons only and are not intended to limit this disclosure in any way. The content of any individual section may be equally applicable to all sections.
Claims
1. A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) protein having an amino acid sequence having at least about 97% identity to SEQ ID NO:1 or SEQ ID NO:2 and having substitutions or deletions at positions N37, E38 and / or T39 or corresponding positions. (a) the amino acid at or corresponding to the N37 position is a polar, neutrally charged hydrophilic amino acid selected from glutamine (Q), serine (S), threonine (T), proline (P), and / or cysteine (C); or (b) the amino acid at or corresponding to position T39 is a hydrophobic aliphatic amino acid selected from alanine (A), glycine (G), leucine (L), isoleucine (I), methionine (M), and / or valine (V); or (c) the amino acid at or corresponding to position E38 is a hydrophobic aliphatic amino acid selected from alanine (A), leucine (L), isoleucine (I), methionine (M), and / or valine (V); The recombinant protein of claim 1.
3. the recombinant protein binds to and / or activates granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-R-α or CSF2R); The GM-CSF-R-α is expressed on the surface of hematopoietic progenitor cells, and the hematopoietic progenitor cells are immune cells and / or irradiated. The recombinant protein of claim 1.
4. The recombinant protein of claim 1, wherein the recombinant human GM-CSF is soluble and / or functionally similar to sargramostim.
5. 2. The recombinant protein of claim 1, wherein the recombinant human GM-CSF comprises multiple molecular forms selected from a non-glycosylated form, an O-glycosylated form, an N-glycosylated form, and an N+O glycosylated form. (a) the recombinant human GM-CSF is substantially free of hypermannosylated forms; (b) the recombinant human GM-CSF resolves into three peaks when quantified by reversed-phase high performance liquid chromatography (RP-HPLC); (c) the recombinant human GM-CSF does not provide a substantial peak with a retention time of less than 20 minutes when quantified by reversed-phase high performance liquid chromatography (RP-HPLC); and / or (d) the recombinant human GM-CSF is substantially free of hypermannosylated forms when purified without the use of organic solvents or a reverse-phase C4 HPLC column; The recombinant protein of claim 1.
7. A nucleic acid molecule having a codon-optimized sequence encoding the recombinant human GM-CSF described in claim 1.
8. A non-human host cell expressing the nucleic acid molecule of claim 7, wherein the host cell is a yeast cell.
9. The host cell of claim 8 , wherein the yeast cell is a non-methylotrophic yeast cell.
10. A pharmaceutical composition comprising the recombinant human GM-CSF of claim 1 and a pharma- ceutically acceptable excipient or carrier.
11. A pharmaceutical composition for treating a patient comprising a therapeutically effective amount of the pharmaceutical composition of claim 10, wherein the patient is are undergoing or have undergone cancer treatment, or are undergoing or have undergone a bone marrow transplant; and / or Previous acute exposure to myelosuppressive amounts of radiation Pharmaceutical compositions.
12. The patient: (a) therapeutically by modulating the clonal expansion, survival, differentiation, and activation state of hematopoietic progenitor cells; (b) by regulating the myelomonocytic lineage by promoting the proliferation of megakaryocytic and erythroid progenitor cells; (c) by modulating hematopoietic progenitor cells by stimulating the survival, proliferation, and activation of neutrophils, macrophages, and / or dendritic cells; and / or (d) treating after bone marrow transplantation by modulating hematopoietic progenitor cells by stimulating survival, proliferation, and activation of neutrophils, macrophages, and / or dendritic cells; The pharmaceutical composition of claim 10.
13. The pharmaceutical composition comprising: Promoting neutrophil recovery after induction chemotherapy and / or reducing the incidence of infections; Mobilizing hematopoietic progenitor cells into peripheral blood for harvesting by leukapheresis and transplantation; To promote bone marrow reconstitution following autologous or allogeneic bone marrow or peripheral blood progenitor cell transplantation; Treating delayed neutrophil recovery or engraftment failure following autologous or allogeneic bone marrow transplantation; and / or To prevent hematopoietic acute radiation syndrome (H-ARS); The pharmaceutical composition of claim 10, wherein the pharmaceutical composition provides one or more of the following:
14. 11. A pharmaceutical composition according to claim 10 for treating a patient infected with coronavirus, comprising an effective amount of a composition comprising recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) protein, the coronavirus is a betacoronavirus selected from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), HCoV-HKU1, and HCoV-OC43; or The coronavirus is an alphacoronavirus selected from HCoV-NL63 and HCoV-229E; The patient is suffering from one or more of the following: fever, cough, shortness of breath, diarrhea, upper respiratory tract symptoms, lower respiratory tract symptoms, pneumonia, and acute respiratory syndrome; the patient is hypoxic; and / or the patient is suffering from respiratory distress; Pharmaceutical compositions. (a) preventing or alleviating the onset of acute respiratory distress syndrome (ARDS) in a patient; (b) improving oxygenation of the patient; (c) preventing or mitigating the transition from respiratory distress to cytokine imbalance in a patient; (d) reversing or preventing pulmonary or systemic cytokine storm and / or a cytokine storm selected from one or more of systemic inflammatory response syndrome, cytokine release syndrome, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis; (e) reversing or preventing overproduction of one or more proinflammatory cytokines selected from one or more of IL-6, IL-1, IL-1 receptor antagonist (IL-1ra), IL-2ra, IL-10, IL-18, TNFα, interferon-γ, CXCL10, and CCL7; and / or (f) reducing the patient's viral load compared to before treatment; The pharmaceutical composition of claim 10.
16. 1. A method for producing a recombinant composition comprising recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), comprising: (a) obtaining a cell, or an extract thereof, transfected with a nucleic acid encoding a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), the nucleic acid comprising an amino acid sequence having at least about 97% identity to SEQ ID NO:2 and having substitutions or deletions at positions N37, G38, and / or T39 or corresponding positions; (b) purifying the GM-CSF from the transfected cells using one or more HPLC columns, wherein the purification is in the absence of organic solvents; (c) collecting the purified GM-CSF, wherein the purified GM-CSF is substantially free of hypermannosylated GM-CSF forms; The method, wherein the cell is a Saccharomyces cerevisiae non-mammalian yeast cell, or a Chinese Hamster Ovary (CHO) mammalian cell.
17. 17. The method of claim 16, wherein during production of the recombinant protein, transfection of mammalian cells increases expression levels of the recombinant protein compared to production methods using non-mammalian cells.
18. The method of claim 16, wherein the recombinant human GM-CSF exhibits enhanced function as compared to sargramostim.
19. 1. A composition comprising a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) protein comprising an amino acid sequence having at least about 97% identity to SEQ ID NO:1 or SEQ ID NO:2 and having an N37Q substitution or a corresponding substitution, the GM-CSF is capable of being isolated substantially free of hyperglycosylated species; The composition, wherein the GM-CSF is isolatable without the need for purification with organic solvents.
